NYSE: MRKMerck & Co Inc Stock
$76.53+0.14 (0.18%)
Updated Jul 22, 2021
MRK Price
$76.53
Fair Value Price
N/A
Market Cap
$193.78B
52 Week Low
$71.72
52 Week High
$87.80
P/E
27.53x
P/B
7.19x
P/S
4.06x
PEG
0.77x
Dividend Yield
3.35%
Revenue
$48.02B
Earnings
$7.03B
Gross Margin
67%
Operating Margin
17.48%
Profit Margin
14.6%
Debt to Equity
2.37
Operating Cash Flow
$11B
Beta
0.67
Next Earnings
Jul 29, 2021
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
55
Industry average
Reasons for this score
MRK ($76.53) is trading below its intrinsic value of $352.60, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
MRK is good value based on its earnings relative to its share price (27.53x), compared to the US market average 28.43x)
Valuation
MRK is good value based on its earnings relative to its share price (27.53x), compared to the US Drug Manufacturers - General industry average (33.42x)
Valuation
MRK News
Valuation
MRK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
27.53x
Industry
33.42x
Market
28.43x
MRK is good value based on its earnings relative to its share price (27.53x), compared to the US market average 28.43x)
Valuation
MRK is good value based on its earnings relative to its share price (27.53x), compared to the US Drug Manufacturers - General industry average (33.42x)
Valuation
MRK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.19x
Industry
5.4x
MRK is poor value based on its book value relative to its share price (7.19x), compared to the US Drug Manufacturers - General industry average (5.4x)
Valuation
MRK price to earnings growth (PEG)
For valuing profitable companies with growth potential
MRK is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.77x)
Valuation
MRK's financial health
Profit margin
Revenue
$12.1B
Net Income
$3.2B
Profit Margin
26.3%
MRK's Earnings (EBIT) of $8.39B can safely cover interest payments on company debt ($31.25B)
Financials
MRK's profit margin has decreased (-6.5%) in the last year from (21.1%) to (14.6%)
Financials
Assets to liabilities
Assets
$90.8B
Liabilities
$63.8B
Debt to equity
1.16
MRK's short-term assets ($26.91B) exceed its short-term liabilities ($26.36B)
Financials
MRK's long-term liabilities ($37.45B) exceed its short-term assets ($26.91B)
Financials
MRK's debt has increased relative to shareholder equity (2.37), over the past 5 years ago (1.25)
Financials
MRK's debt to equity ratio (2.37) is considered high
Financials
Cash flow
Operating
$1.8B
Investing
-$738.0M
Financing
-$2.1B
MRK's operating cash flow ($11.34B) is sufficient to service the company's debt ($31.25B)
Financials
Merck & Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.